BRCA
germline mutations
ovarian cancer
survival
Journal
Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503
Informations de publication
Date de publication:
03 11 2021
03 11 2021
Historique:
received:
06
10
2021
revised:
28
10
2021
accepted:
01
11
2021
entrez:
13
12
2021
pubmed:
14
12
2021
medline:
24
3
2022
Statut:
epublish
Résumé
High grade serous ovarian carcinoma (HGSOC) is the most lethal type of epithelial ovarian cancer, with a prevalence of germline A total of 51 women with In our study cohort, 35 patients were carriers of germline mutations in Among HGSOC patients,
Sections du résumé
BACKGROUND
High grade serous ovarian carcinoma (HGSOC) is the most lethal type of epithelial ovarian cancer, with a prevalence of germline
METHODS
A total of 51 women with
RESULTS
In our study cohort, 35 patients were carriers of germline mutations in
CONCLUSIONS
Among HGSOC patients,
Identifiants
pubmed: 34898566
pii: curroncol28060377
doi: 10.3390/curroncol28060377
pmc: PMC8628789
doi:
Substances chimiques
BRCA1 Protein
0
BRCA1 protein, human
0
BRCA2 Protein
0
BRCA2 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4446-4456Références
J Clin Oncol. 2012 Jul 20;30(21):2654-63
pubmed: 22711857
Lancet. 2017 Oct 28;390(10106):1949-1961
pubmed: 28916367
Oncogene. 2003 Sep 1;22(37):5784-91
pubmed: 12947386
Gynecol Oncol. 2017 Jul;146(1):58-63
pubmed: 28454659
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Br J Cancer. 2011 Oct 11;105(8):1114-22
pubmed: 21989215
Cancer Genet. 2012 Jan-Feb;205(1-2):34-41
pubmed: 22429596
Fam Cancer. 2004;3(1):1-10
pubmed: 15131399
Nature. 2019 Jul;571(7766):576-579
pubmed: 31292550
BMC Cancer. 2020 Mar 12;20(1):204
pubmed: 32164585
Gynecol Oncol. 2019 Aug;154(2):441-448
pubmed: 31118141
Nat Genet. 1995 Dec;11(4):428-33
pubmed: 7493024
Cancer Cell. 2011 Dec 13;20(6):797-809
pubmed: 22172724
Cell Oncol (Dordr). 2011 Apr;34(2):71-88
pubmed: 21336636
Cancer Epidemiol Biomarkers Prev. 2002 Apr;11(4):329-36
pubmed: 11927492
Nat Genet. 1997 Jan;15(1):103-5
pubmed: 8988179
Hum Mol Genet. 2001 Apr;10(7):705-13
pubmed: 11257103
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
Cell. 2002 Jan 25;108(2):171-82
pubmed: 11832208
Mol Cell. 2001 Feb;7(2):263-72
pubmed: 11239455
N Engl J Med. 2016 Dec;375(22):2154-2164
pubmed: 27717299
Gynecol Oncol. 2021 Mar;160(3):786-792
pubmed: 33375991
Am J Hum Genet. 2001 Feb;68(2):410-9
pubmed: 11170890
Comput Struct Biotechnol J. 2012 Apr 1;1(1):
pubmed: 22737296
J Clin Oncol. 2020 Oct 20;38(30):3528-3537
pubmed: 32749942
N Engl J Med. 2019 Dec 19;381(25):2416-2428
pubmed: 31851799
JAMA. 2011 Oct 12;306(14):1557-65
pubmed: 21990299
Nat Rev Clin Oncol. 2013 Apr;10(4):211-24
pubmed: 23381004
Nat Genet. 1996 Mar;12(3):298-302
pubmed: 8589721
Eur J Surg Oncol. 2020 Jul;46(7):1327-1333
pubmed: 32085925
N Engl J Med. 2018 Dec 27;379(26):2495-2505
pubmed: 30345884
Eur J Surg Oncol. 2019 Nov;45(11):2096-2102
pubmed: 31227342
Cancer Discov. 2015 Nov;5(11):1137-54
pubmed: 26463832
Nat Rev Cancer. 2011 Dec 23;12(1):68-78
pubmed: 22193408
Int J Cancer. 2020 Sep 1;147(5):1334-1342
pubmed: 32022259
Lancet Oncol. 2014 Jul;15(8):852-61
pubmed: 24882434
N Engl J Med. 2019 Dec 19;381(25):2391-2402
pubmed: 31562799
Clin Cancer Res. 2018 Jan 15;24(2):326-333
pubmed: 29084914
Breast J. 2015 May-Jun;21(3):260-7
pubmed: 25789811